Essex Property Trust will release its first-quarter earnings later this month, and analysts anticipate a single-digit bottom-line growth.
Essex Property Trust, Inc. ESS is well-poised to gain from a robust property base in the West Coast market with several demand drivers. Efforts to leverage technology, scale and organizational capabilities...
The first quarter of 2025 brought a wave of strong apartment demand, offering a lift to occupancy and rent growth as the supply surge begins to wane.Per RealPage data, from January through March 2025,...
Buying high-quality dividend stocks is a great way to collect passive dividend income. The best ones increase their dividends each year, and they can help you more than offset the impact of inflation over...
Given Essex Property Trust’s recent outperformance relative to the Nasdaq, analysts remain moderately optimistic about the stock’s prospects.
Essex Property Trust has significantly outperformed the broader market over the past year and analysts remain moderately bullish on the stock’s prospects.
Boosting shareholders’ wealth, Prologis, Inc. PLD announced a 5% hike in its quarterly cash dividend to $1.01 per share from 96 cents paid out in the prior quarter. The increased dividend will be paid...
AvalonBay Communities AVB reported fourth-quarter 2024 core funds from operations (FFO) per share of $2.80, missing the Zacks Consensus Estimate of $2.83. However, the figure climbed 2.2% from the prior-year...
Shares of Mid-America Apartment Communities MAA, commonly known as MAA, witnessed a 1.13% fall in the pre-market trading hours today after it came up with lower-than-expected fourth-quarter 2024 results...
UDR Inc. UDR reported fourth-quarter 2024 funds from operations as adjusted (FFOA) per share of 63 cents, in line with the Zacks Consensus Estimate. The figure remained unchanged year over year.Stay up-to-date...
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to...
LONDON, UK / ACCESSWIRE / April 1, 2022 / Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF), the brand-led consumer goods company focussed on CBD health and wellness solutions, is pleased to announce that it...
SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of...
FDA End-of-Phase 2 meeting provides development pathway for efzofitimod (ATYR1923) in pulmonary sarcoidosis; planned registrational study to initiate in...
Regulatory path forward supports company’s intention to initiate a planned registrational study in the third quarter of 2022....
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of...
Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT...
LONDON, UK / ACCESSWIRE / March 4, 2022 / Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF), the brand-led consumer goods company focused on CBD health and wellness solutions, announces that, on 11 February...
Love Hemp a Winner in this Year's Beauty Shortlist Awards LONDON, UK / ACCESSWIRE / March 3, 2022 / Love Hemp Group PLC ("Love Hemp", the "Group", or the "Company") (AQSE:LIFE)(OTCQB:WRHLF), the brand-led...
LONDON, UK / ACCESSWIRE / February 28, 2022 / For the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, Love Hemp (LSE:LIFE) (OTCQB:WRHLF) announces that the Company...
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to...
LONDON, UK / ACCESSWIRE / April 1, 2022 / Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF), the brand-led consumer goods company focussed on CBD health and wellness solutions, is pleased to announce that it...
SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of...
FDA End-of-Phase 2 meeting provides development pathway for efzofitimod (ATYR1923) in pulmonary sarcoidosis; planned registrational study to initiate in...
Regulatory path forward supports company’s intention to initiate a planned registrational study in the third quarter of 2022....
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of...
Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT...
LONDON, UK / ACCESSWIRE / March 4, 2022 / Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF), the brand-led consumer goods company focused on CBD health and wellness solutions, announces that, on 11 February...
Love Hemp a Winner in this Year's Beauty Shortlist Awards LONDON, UK / ACCESSWIRE / March 3, 2022 / Love Hemp Group PLC ("Love Hemp", the "Group", or the "Company") (AQSE:LIFE)(OTCQB:WRHLF), the brand-led...
LONDON, UK / ACCESSWIRE / February 28, 2022 / For the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, Love Hemp (LSE:LIFE) (OTCQB:WRHLF) announces that the Company...